COST-CONSEQUENCES ANALYSIS OF COFORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE IN PATIENT POPULATIONS WITH DIFFERING RISK PROFILES
| Title: | COST-CONSEQUENCES ANALYSIS OF COFORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE IN PATIENT POPULATIONS WITH DIFFERING RISK PROFILES |
|---|---|
| Authors: | Gallant, J.; Altice, F.; Folse, H.J. |
| Source: | Value in Health ; volume 19, issue 3, page A214 ; ISSN 1098-3015 |
| Publisher Information: | Elsevier BV |
| Publication Year: | 2016 |
| Collection: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| Document Type: | article in journal/newspaper |
| Language: | English |
| DOI: | 10.1016/j.jval.2016.03.1206 |
| Availability: | http://dx.doi.org/10.1016/j.jval.2016.03.1206; https://api.elsevier.com/content/article/PII:S1098301516012742?httpAccept=text/plain; https://api.elsevier.com/content/article/PII:S1098301516012742?httpAccept=text/xml |
| Rights: | https://www.elsevier.com/tdm/userlicense/1.0/ ; https://www.elsevier.com/open-access/userlicense/1.0/ |
| Accession Number: | edsbas.783BE261 |
| Database: | BASE |